Home » Stocks » Atossa Therapeutics

Atossa Therapeutics, Inc. (ATOS)

Stock Price: $3.71 USD 0.32 (9.44%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $3.78 +0.07 (1.89%) Aug 14, 5:54 PM

Stock Price Chart

Key Info

Market Cap 34.16M
Revenue (ttm) n/a
Net Income (ttm) -12.76M
Shares Out 9.21M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $3.71
Previous Close $3.39
Change ($) 0.32
Change (%) 9.44%
Day's Open 3.42
Day's Range 3.36 - 3.85
Day's Volume 1,511,868
52-Week Range 0.76 - 5.08

More Stats

Market Cap 34.16M
Enterprise Value 26.63M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 9.21M
Float 9.18M
EPS (basic) -1.37
EPS (diluted) -1.76
FCF / Share -1.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 235,331
Short Ratio 0.18
Short % of Float 1.95%
Beta 2.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.24
Revenue n/a
Operating Income -12.80M
Net Income -12.76M
Free Cash Flow -9.94M
Net Cash 7.53M
Net Cash / Share 0.82
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -61.43%
ROE -106.04%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $3.71
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-----95.62%-93.65%31.28%32022.8%-
Gross Profit-----
Operating Income-17.27-11.43-7.65-7.97-12.76-12.17-10.78-5.07-3.43
Net Income-17.24-11.40-8.12-6.37-15.76-14.66-10.78-5.08-3.44
Shares Outstanding8.504.160.970.
Earnings Per Share-2.03-5.50-10.97-25.92-99.72-109.80-126.00-73.80-68.40
Operating Cash Flow-9.13-8.96-6.59-5.37-13.95-10.56-8.83-3.90-3.49
Capital Expenditures-0.01-0.11--0.01-0.130.16-0.24-0.10-0.14
Free Cash Flow-9.14-9.07-6.59-5.38-14.08-10.40-9.07-4.00-3.63
Cash & Equivalents12.6910.497.273.083.998.506.341.732.91
Total Debt0.04-----0.02-1.01
Net Cash / Debt12.6510.497.273.083.998.506.331.731.91
Book Value13.168.816.943.103.749.5010.605.181.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Atossa Therapeutics, Inc.
Country United States
Employees 4
CEO Steven C. Quay

Stock Information

Ticker Symbol ATOS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATOS
IPO Date November 8, 2012


Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. Its lead program is the development of Endoxifen, conducting two Phase II studies, which is an active metabolite of tamoxifen to treat and prevent breast cancer. The company is also developing intraductal microcatheter technology to potentially target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. Its medical devices also include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator, which collect specimens of nipple aspirate fluid for cytological testing. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.